5-flourouracil–induced encephalopathy in parkinson's disease

Kaynakça (1)

1. Ardalan B, Chua L, Tian EM, et al. A phase II study ofweekly 24-hour infusion of high-dose flourouracil withleucoverin in colorectal carcinoma. J Clin Oncol 9:625-30, 1991. 2.Yeh KH, Cheng AL. High-dose 5-flourouracil infusionaltherapy associated with hyperammonemia, lactic aci-dosis and encephalopathy. Brit J Cancer 75: 464-465,1997. 3.Weiss HD, Walker MD, Wiernik PH. Neurotoxicity ofcommonly used antineoplastic agents (first of twoparts). N Engl J Med 291: 75-81, 1974. 4.Lucato LT, Mc Kinney AM, Short J, et al. Reversiblefindings of restricted diffusion in 5-fluorouracil neuroto-xicity. Australas Radiol 50: 364-368, 2006. 5. Koenig H, Patel A. Biochemical basis for fluorouracilneurotoxicity. Arch Neurol 23: 155-160, 1970. 6.Takimoto CH, Lu ZH, Zhang R, et al. Severe neuroto-xicity following 5-fluorouracil-based chemotherapy in apatient with dihydropyrimidine dehidrogenase defici-ency. Clin Cancer Res 2: 477-481, 1996. 7. Liaw CC, Wang HM, Wang CH, et al. Risk of transienthyperammonemic encephalopathy in cancer patientswho received continuous infusion of 5-flourouracil withthe complication of dehydration and infection. Antican-cer Drugs 10: 275-281, 1999. 8.Yadav BS, Sharma SC. 5-Fluorouracil associated en-cephalopathy. Indian J Pharmacol 37: 129-131, 2005. 9.Pidoplichko VI, Dani JA. Acid-sensitive ionic channelsin midbrain dopamine neurons are sensitive to ammo-nium, which may contribute to hyperammonemiadamage. Proc Nati Acad Sci 103: 11376-11380,2006